Tigecycline

Kathryn Dzintars, Pharm.D., BCPS

INDICATIONS

FDA

  • Complicated skin and skin structure infections (including those caused by MRSA and vancomycin-susceptible E. faecalis).
    • Author’s comment: avoid in severe infections +/- bacteremia.
  • Complicated intra-abdominal infections (as a single agent).
    • Author’s comment: avoid in severe infections +/- bacteremia.
  • Community-acquired bacterial pneumonia caused by S. pneumoniae (PCN-susceptible isolates), H. influenzae (beta-lactamase negative isolates), and Legionella pneumophila.
    • Author’s comment: not a first-line agent and generally not used for CAP.

NON-FDA APPROVED USES

  • HAP/VAP due to MDR GNR, but high rates of clinical failure reported[5].
    • In critically ill patients, consider using tigecycline in combination with carbapenem or colistin.

There's more to see -- the rest of this topic is available only to subscribers.

© 2000–2025 Unbound Medicine, Inc. All rights reserved